# Anlongmed Fund

> Anlongmed Fund is a VC fund in Beijing backing Health Care, Medical and Biotechnology. See 9 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 9
- Last investment: Jan 2021
- Lead investor: 33%
- Last updated: Sep 2026
- Website: http://anlongmed.com/en/

Anlongmed Fund is a VC fund in Beijing focused on Health Care and Medical. AnlongMed is a venture capital fund focuses on early stage life science and healthcare sectors. It is managed by a team led by Dr. Adam Zhao Chunlin, a veteran in life science with 30 years of experience, along with professionals with MNC, R&D, clinical, entrepreneurial and investment experience in both U.S. and China. The fund is anchored byChinese Academy of Sciences. With extensive experience and connections from Chinese Academy of Sciences, Tsinghua University, Peking Union Medical College, and Bayhelix Group, AnlongMed strives to help entrepreneurs to start a venture in life science and healthcare in China. The fund has invested 22 firms from its first phase， including Netvation, a joint initiative toward new drug development between Chinese Academy of Science and Pfizer, Inc, 4 companies founded together with entrepreneurs across life science, biopharmaceutical, medical devices, and healthcare services.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 6 | 67% |
| Medical | 3 | 33% |
| Biotechnology | 3 | 33% |
| Medical Device | 1 | 11% |
| Information Technology | 1 | 11% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 56% |
| Series B | 2 | 22% |
| Seed | 1 | 11% |
| Angel | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Skynor Medical | Skynor Medical is a minimally invasive vascular intervention equipment supplier. |  | Series B | Jan 20, 2021 |  |
| Sophonix | Sophonix focuses on the development, production and sales of in vitro diagnostic instruments and reagents, providing accurate POCT solutions. | $14.2M | Series B | Jun 23, 2020 |  |
| Zhenzhun Biotech | It is a bio-tech enterprise integrating R&D, production and sales of in vitro diagnostic equipment consumables. Life and health business. The core team includes both enterprise management experts from leading medical device companies in the world, as well as scientists and technical experts in micro-nano processing, precision instruments, imagealgorithms, and biological reagents. We have successfully developed China's first chip-type digital PCR instrument with independent intellectual property rights. 臻Quan Biotechnology is in the stage of rapid development, and we invite talented people to join us to create a great cause! |  | Series A | Aug 01, 2019 |  |
| Laekna Therapeutics | Laekna Therapeutics is a startup biotech company focusing on innovative drug discovery and development. Targeting large unmet medical needs, Laekna is dedicated to developing new therapies for cancer and liver diseases. | $18.5M | Series A | Jun 04, 2018 |  |
| Jun Hui Biotech | Healthcare company based in Suzhou. |  | Seed | May 08, 2018 |  |
| Sonmol | Sonmol provides products and services in the respiratory field. Their mature nasal care products include the maternal and child care series, household cleaning series, and personal care series. They also provide online services for patients with chronic respiratory diseases. Their goal is to provide intelligent healthcare through technologicalinnovation. | $1.5M | Series A | Sep 30, 2017 |  |
| Hanyu Medical | Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases. |  | Series A | Sep 14, 2017 |  |
| Qianglian Zhichuang | Qianglian Zhichuang is the first high-tech company in China to focus on the pain points of cerebrovascular disease treatment. |  | Angel | Jan 01, 2017 |  |
| FitSAMO | FitSAMO is an orthopaedic surgical equipment supplier. |  | Series A | Mar 01, 2016 |  |

9 of 9 investments shown.

## Co-investors
- [C-Bridge Capital](https://shizune.co/investors/profile/cbridge-capital) — VC Fund, 1 deal together
- [Delian Capital](https://shizune.co/investors/profile/delian-capital) — VC Fund, 1 deal together
- [ETP Fund](https://shizune.co/investors/profile/etp-fund) — VC Fund, 1 deal together
- GoldTech — VC Fund, 1 deal together
- [Med-Fine Capital](https://shizune.co/investors/profile/med-fine-capital) — VC Fund, 1 deal together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Anlongmed Fund invest in?

Anlongmed Fund invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Anlongmed Fund last invest?

The most recent investment recorded for Anlongmed Fund closed in Jan 2021. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co